Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.
Beypınar İ, Demir H, Yaslıkaya Ş, Köşeci T, Demir B, Çolak G, Ağaoğlu AB, Şahbazlar M, Şancı PC, Çabuk D, Işık U, Şahin E, Coşkun A, Caner B, Aykut T, Artaç M, Duygulu ME, Sever N, Öksüz S, Turan N, Aykan MB, Tüzün EK, Uysal M, Uğurlu İ, Sakin A, Acar C, Özaşkın D, Şakalar T, Keskinkılıç M, Yavuzşen T, Köse N, Ertürk İ, Yıldırım N, Balçık OY, Alkan A, Selvi O, Erçin E, Ünal OÜ, Karaçin C. Beypınar İ, et al. Among authors: uysal m. Breast Cancer Res Treat. 2024 Dec;208(3):597-604. doi: 10.1007/s10549-024-07456-x. Epub 2024 Aug 9. Breast Cancer Res Treat. 2024. PMID: 39123071
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Bilici A, et al. Among authors: uysal m. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22. Cancer Invest. 2022. PMID: 34894960
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Araz M, Karaagac M, Korkmaz L, Koral L, Inci F, Beypinar I, Uysal M, Artac M. Araz M, et al. Among authors: uysal m. Cancer Chemother Pharmacol. 2019 Jun;83(6):1091-1097. doi: 10.1007/s00280-019-03831-4. Epub 2019 Apr 8. Cancer Chemother Pharmacol. 2019. PMID: 30963213
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S, Ozturk A, Karadurmus N, Korkmaz T, Yumuk PF, Cicin I, Paydas S, Cilbir E, Sakalar T, Uysal M, Yesil Cinkir H, Uskent N, Demir N, Sakin A, Dursun OU, Aver B, Turhal NS, Keskin S, Tural D, Eralp Y, Bugdayci Basal F, Yasar HA, Sendur MAN, Demirci U, Cubukcu E, Karaagac M, Cakar B, Tatli AM, Yetisyigit T, Urvay S, Gursoy P, Oyan B, Turna ZH, Isikdogan A, Olmez OF, Yazici O, Cabuk D, Seker MM, Unal OU, Meydan N, Okutur SK, Tunali D, Erman M; Lung Sub-Group Study of the Turkish Oncology Group. Kilickap S, et al. Among authors: uysal m. Medicine (Baltimore). 2024 May 24;103(21):e37972. doi: 10.1097/MD.0000000000037972. Medicine (Baltimore). 2024. PMID: 38787994 Free PMC article.
Merkel cell carcinoma in Turkey: A multicentric study.
Yildiz F, Demirci U, Küçükarda A, Büyüksimsek M, Sakalar T, Topcu TO, Aslan F, Tufan G, Aydin O, Turna H, Babacan NA, Basoglu T, Kurt B, Yildiz B, Eren T, Demiray AG, Gumusay O, Arslan C, Özdemir N, Urun Y, Baykara M, Turan N, Uysal M, Bilici A, Kavgaci H, Çiçin İ, Kilickap S, Paydas S. Yildiz F, et al. Among authors: uysal m. J Cancer Res Ther. 2021 Oct-Dec;17(6):1525-1529. doi: 10.4103/jcrt.JCRT_950_19. J Cancer Res Ther. 2021. PMID: 34916389 Free article.
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.
Gürbüz M, Kiliçkap S, Bilici A, Karadurmuş N, Sezer A, Şendur MAN, Paydaş S, Artaç M, Fulden Yumuk P, Gürsoy P, Uysal M, Şenol Coşkun H, Tatli AM, Selçukbiricik F, Dişel U, Köksoy EB, Güven DC, Uğrakli M, Akkuş E, Yücel Ş, Erol C, Karakaya S, Şakalar T, Khanmammadov N, Paksoy N, Demirkazik A. Gürbüz M, et al. Among authors: uysal m. Medicine (Baltimore). 2022 Dec 16;101(50):e32368. doi: 10.1097/MD.0000000000032368. Medicine (Baltimore). 2022. PMID: 36550824 Free PMC article.
431 results